Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teprasiran - Quark-Pharmaceuticals

Next Previous
Drug Profile

Teprasiran - Quark-Pharmaceuticals

Alternative Names: AKIi-5; DGFi; I-5NP; QPI-1002; QPI002; Teprasiran sodium

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Quark Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference; Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function
  • New Molecular Entity No

Highest Development Phases

  • Phase III Delayed graft function
  • Phase I/II Acute kidney injury

Most Recent Events

  • 12 Dec 2024 No development reported - Phase-III for Acute kidney injury (In the elderly, Prevention, In adults) in Germany, Canada, United Kingdom, Spain, France, New Zealand, Czech Republic, Belgium, Austria, Australia, USA (IV)
  • 08 Jan 2019 Quark Pharmaceuticals completes the phase III ReGIFT trial in Delayed graft function (Prevention) in USA, Spain, Czech Republic, Belgium, Netherlands, Argentina, Australia, Brazil, Canada, France and Germany (IV) (NCT02610296)
  • 25 May 2018 Phase-III clinical trials in Acute kidney injury (Prevention, In adults, In the elderly) in USA (IV) (NCT03510897)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top